Calithera Biosciences

Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients.

Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors.

In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

South San Francisco, US
35 (est)

Calithera Biosciences Locations

South San Francisco, US

Calithera Biosciences Metrics

Calithera Biosciences Summary

Founding Date


Market capitalization

$46.8 M

Closing share price


Calithera Biosciences Market Value History

Calithera Biosciences News

Calithera Biosciences Company Life